Otsuka Pharmaceutical Acquires Jnana Therapeutics

Otsuka Pharmaceutical Acquires Transcend Therapeutics

March 27, 2026

Biotechnology

Otsuka Pharmaceutical Co., Ltd. entered into an agreement to acquire clinical-stage biotech company Transcend Therapeutics, which is developing rapid-acting treatments for neuropsychiatric disorders, including its lead program TSND-201 (methylone) for PTSD. Otsuka would pay $700 million upfront at closing and up to $525 million in contingent milestone payments, with completion expected in Q2 2026; the acquisition has since been completed.

Johnson & Johnson Acquires Intra-Cellular Therapies

April 2, 2025

Healthcare Services

Johnson & Johnson has acquired Intra-Cellular Therapies, paying $132 per share in cash for all outstanding shares, for an equity value of approximately $14.6 billion. The deal adds CAPLYTA (lumateperone) and a clinical-stage pipeline, including ITI-1284, to strengthen J&J’s neuroscience portfolio.

Otsuka Pharmaceutical Acquires Mindset Pharma

August 31, 2023

Biotechnology

Otsuka Pharmaceutical Co., Ltd., through its wholly owned U.S. subsidiary Otsuka America, Inc., agreed to acquire Mindset Pharma Inc. in an all-cash statutory plan of arrangement valued at approximately CAD 80 million. The acquisition adds Mindset’s next-generation psychedelic and non-psychedelic drug discovery assets and synthesis capabilities to Otsuka’s psychiatry and neurology pipeline.

Shionogi Inc. Acquires Qpex Biopharma, Inc.

June 26, 2023

Pharmaceuticals

Shionogi Inc., the U.S. subsidiary of Shionogi & Co., Ltd., entered into a definitive agreement to acquire San Diego-based clinical-stage antimicrobial developer Qpex Biopharma, Inc. The acquisition (upfront $100 million plus up to $40 million in milestones) brings Qpex's investigational beta-lactamase inhibitor xeruborbactam and expands Shionogi's infectious disease R&D capabilities and pipeline.

Shionogi Acquires Tetra Therapeutics

May 26, 2020

Biotechnology

Shionogi & Co., Ltd. agreed to acquire clinical-stage biopharmaceutical company Tetra Therapeutics, giving Shionogi global rights to Tetra's portfolio including BPN14770. The deal, announced May 26, 2020, is valued at up to $500 million in milestone and contingent payments.

PTC Therapeutics to Acquire Censa Pharmaceuticals

May 6, 2020

Biotechnology

PTC Therapeutics has entered into an agreement to acquire Censa Pharmaceuticals to obtain CNSA-001 (sepiapterin), a Phase 3–ready oral therapy for phenylketonuria (PKU) and other BH4-pathway disorders. Under the deal PTC will pay approximately $10 million cash upfront and up to 850,000 shares of PTC common stock, plus potential development, regulatory and sales milestones totaling hundreds of millions of dollars.